Chris Colucci, vice president of information technology at Insmed, sits down with Nagaraja Srivatsan to discuss the company’s shift from AI experimentation to enterprise-scale adoption, using the patient as its North Star guiding decisions across the drug development value chain. He outlines the evolution of Insmed’s AI journey and explains how the company now evaluates opportunities through clear lenses of game-changing impact, productivity gains, and automation. Colucci also discusses what it takes to operationalize AI in an emerging biotech, the practical steps Insmed has taken to scale AI across the value chain, and how anchoring decisions to the goal of getting therapies to patients faster helps prioritize where AI can be most transformative.

Vikram Nair, chief information officer of Amneal Pharmaceuticals, joins Srivatsan Nagaraja to break down what it really takes to turn AI from boardroom buzz into real business impact. From early missteps and skeptical stakeholders to building smarter metrics, Nair shares lessons from the front lines of AI transformation—and introduces a practical control framework to help life sciences companies scale AI, manage risk, and evolve without losing control.

Dennis Salotti, executive director and head of clinical outsourcing and innovation at Jazz Pharmaceuticals, joins Srivatsan Nagaraja to talk about what AI really looks like in day-to-inside a drug company. He explains how large language models and agentic tools can streamline contracting, budgeting, and risk management—mundane but high-impact work that speeds studies and improves trial-site experience. Salotti shares how to design narrow, high‑ROI pilots, build AI fluency, avoid “AI slop,” and turn AI into a thinking partner rather than a shortcut, stacking small wins that remove grunt work, capture lessons learned, and elevate people from doers to critical thinkers.